Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era

References

• Haverkos BM, Pan Z, Gru AA, et al. Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016;11:514–527.
   PubMed Web of Science ®Google Scholar
• Ying Z, Zhu J. Extranodal natural killer/T cell lymphoma: we should and we can do more. Chin Clin Oncol. 2015;4:12.
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931–3937.
   PubMed Web of Science ®Google Scholar
• Vazquez A, Khan MN, Blake DM, et al. Extranodal natural killer/T-cell lymphoma: a population-based comparison of sinonasal and extranasal disease. Laryngoscope. 2014;124:888–895.
   PubMed Web of Science ®Google Scholar
• Vasquez J, Serrano M, Lopez L, et al. Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience. Ecancer. 2016;10:688.
   PubMed Web of Science ®Google Scholar
• Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer. 1998;83:449–456.
   PubMed Web of Science ®Google Scholar
• Niu SQ, Yang Y, Li YY, et al. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma. Chin J Cancer. 2016;35:34.
   PubMedGoogle Scholar
• Fang H, Jin J, Wang WH, et al. Prognostic factors and treatment outcomes for patients with stage II extranodal nasal-type natural killer/T-cell lymphoma of the upper aerodigestive tract. Leuk Lymphoma. 2014;55:1832–1837.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang YJ, Zhu Y, et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter study. Leukemia. 2015;29:1571–1577.
   PubMed Web of Science ®Google Scholar
• Lee J, Kim CY, Park YJ, et al. Sequential chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. Blood Res. 2013;4:274–281.
   Google Scholar
• Kwong YL, Kim SJ, Tse E, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol. 2018;29:256–263.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013;121:4997–5005.
   PubMed Web of Science ®Google Scholar
• Zhang L, Jiang M, Xie L, et al. Five-year analysis from phase 2 trial of "sandwich" chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer Med. 2016;5:33–40.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang H, Jiang Y, et al. Phase 2 trial of "sandwich" l-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118:3294–3301.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120:2973–2980.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang ZH, Chen XQ, et al. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long-term follow-up. Oncol Lett. 2015;10:1036–1040.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Oguchi M. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type. Blood. 2018;131:2528–2540.
   PubMed Web of Science ®Google Scholar
• Shen Q, Ma X, Hu W, et al. Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for stage I–II natural killer/T-cell lymphoma nasal type: dosimetric and clinical results. Radiat Oncol. 2013;8:152.
   PubMed Web of Science ®Google Scholar
• Wang H, Li YX, Wang WH, et al. Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1115–1121.
   PubMed Web of Science ®Google Scholar
• Kim TM, Heo DS. Extranodal NK/T-cell lymphoma, nasal type: new staging system and treatment strategies. Cancer Sci. 2009;100:2242–2248.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17:389–400.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103–111.
   PubMed Web of Science ®Google Scholar
• You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618–625.
   PubMed Web of Science ®Google Scholar
• Kim TH, Kim JS, Suh YG, et al. The roles of radiotherapy and chemotherapy in the era of multimodal treatment for early-stage nasal-type extranodal natural killer/T-cell lymphoma. Yonsei Med J. 2016;57:846–854.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Li YX, Wang H, Jin J, et al. Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2012;82:1809–1815.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006;24:181–189.
   PubMed Web of Science ®Google Scholar
• Jiang L, Li SJ, Jiang YM, et al. The significance of combining radiotherapy with chemotherapy for early stage extranodal natural killer/T-cell lymphoma, nasal type: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55:1038–1048.
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54–63.
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Wang WH, et al. Failure patterns and clinical implications in early stage nasal natural killer/T-cell lymphoma treated with primary radiotherapy. Cancer. 2011;117:5203–5211.
   PubMed Web of Science ®Google Scholar
• Tse E, Kwong YL. Nasal NK/T-cell lymphoma: RT, CT, or both. Blood. 2015;126:1400–1401.
   PubMed Web of Science ®Google Scholar
• Huang M, Jiang Y, Liu W, et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys. 2008;70:166–174.
   PubMed Web of Science ®Google Scholar
• Zang J, Li C, Luo SQ, et al. Early radiotherapy has an essential role for improving survival in patients with stage I–II nasal-type of NK/T cell lymphoma treated with l-asparaginase-containing chemotherapy – a single institution experience. Ann Hematol. 2015;94:583–591.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu Y, Cao JZ, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015;126:1424–1432.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009;114:4771–4776.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhang YJ, Lin XB, et al. Role of radiotherapy and prognosis analyses in patients with early stage extranodal nasal type NK/T-cell lymphoma treated predominantly with initial chemotherapy. Int J Radiat Oncol Biol Phys. 2010;78:S548.
   Web of Science ®Google Scholar
• Yang Y, Cao J, Lan S, et al. Association of improved locoregional control with prolonged survival in early-stage extranodal nasal-type natural killer/T-cell lymphoma. JAMA Oncol. 2017;3:83.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Dong M, He XH, et al. GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. Medicine (Baltimore). 2016;95:e2787.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yang D, Kim JS, et al. Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93:1895–1901.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009;27:5594–5600.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol. 2009;27:6027–6032.
   PubMed Web of Science ®Google Scholar
• Bi XW, Xia Y, Zhang WW, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94:1525–1533.
   PubMed Web of Science ®Google Scholar